echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Deck Pharma's first new drug approved in China

    Deck Pharma's first new drug approved in China

    • Last Update: 2021-12-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Pharmaceutical Guanlan

    On December 16, the official website of China's National Medical Products Administration (NMPA) announced that a new anti-cancer drug Selinexor (ATG-010) was approved


    It is worth mentioning that this is a new drug introduced by Deqi Pharma, and it is also the first new drug approved in China by Deqi Pharma since its establishment


    Image source: NMPA official website

    Celiniso was originally developed by Karyopharm Therapeutics


    In the United States, Celiniso has been approved by the FDA to treat multiple indications, including multiple myeloma and diffuse large B-cell lymphoma


    Earlier, Deqi Pharmaceuticals obtained the exclusive development and commercialization rights of Celiniso in many Asia-Pacific markets including Greater China and South Korea


    At the end of July this year, Deqi Pharmaceuticals announced that the new drug listing application of Celiniso and dexamethasone has been approved by the Ministry of Food and Drug Safety (MFDS) priority review process for the treatment of at least four previous treatments (including Four-line therapy including two proteasome inhibitors, two immunomodulators, and CD38 monoclonal antibody) for adult patients with relapsed or refractory multiple myeloma, and single-agent therapy for relapsed or refractory patients who have previously received at least second-line treatment Treatment of adult patients with diffuse large B-cell lymphoma (rrDLBCL)


    In early 2021, Celiniso submitted a new drug marketing application in China and was included in the priority review in February


    According to public news, Deqi Pharmaceutical has made preparations in advance for the commercialization of the drug


    Reference materials:

    [1] Information to be obtained for the drug approval certificate issued by the National Medical Products Administration of China on December 16.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.